Targeted FAP chimeric antigen receptor regulatory T cell, and preparation method and application thereof
By targeting chimeric antigen receptor regulatory T cells of fibroblast activation protein, the problem of limited number of Tregs and limited therapeutic effect of polyclonal Tregs is solved, the specificity and safety of heart healing are achieved, the side effects are reduced, and the side effects are improved are improved. The therapeutic effect.
Patent Information
- Application Number
- CN202411100427.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing Tregs are limited in number and the treatment effect of polyclonal Tregs is limited, there is a risk of nonspecific immunosuppression, and the rarity of antigen-specific Tregs makes cardiac healing treatment challenging.
Develop chimeric antigen receptor (CAR) regulatory T cells targeting fibroblast activation protein (FAP), introducing FAP-targeting CAR into Tregs through recombinant viral vectors, redirecting to heart tissue to control fibrosis and inflammatory responses .
It improves the specificity and safety of heart healing, reduces cardiac fibrosis, reduces the degree of heart remodeling, reduces inflammation, enhances cardiac function repair, reduces the side effects of traditional immunosuppressants, and improves the therapeutic effect.
Smart Images

Figure CN119060202A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical technology, and in particular relates to a chimeric antigen receptor regulatory T cell targeting FAP, and a preparation method and application thereof. Background Art
[0002] Myocardial infarction (MI) is one of the leading causes of death worldwide and poses a huge challenge to cardiac repair. In particular, MI survivors who miss the critical time window for emergency reperfusion therapy are often at risk of chronic heart failure (HF) due to insufficient myocardial repair. To meet this urgent need, effective interventions that can effectively promote cardiac healing need to be identified and developed.
[0003] Regulatory T cells (Tregs) play a crucial role in immune homeostasis by suppressing innate and adaptive immune responses and have recently been implicated in cardiac repair after MI. Experimental studies have consistently demonstrated that increasing Treg numbers, either by infusion of polyclonal Tregs or by using superagonist anti-CD28 antibodies, improves cardiac function after injury. The critical role of Tregs in regulating fibrosis and modulating inflammatory responses opens up exciting possibilities for Treg-based cell therapy in enhancing cardiac healing after MI. However, despite the promising results of Treg therapy, there are several limitations that must be addressed. A major challenge is the limited number of Tregs available for therapy, as they comprise only a small fraction of circulating CD4 + 2–8% of T cells, making it difficult to obtain sufficient numbers of cells to produce a significant therapeutic effect. In addition, infusion of polyclonal Tregs has shown limited effects and carries the risk of nonspecific immunosuppression. Another obstacle is the limited availability and rarity of antigen-specific Tregs, making their generation challenging. Therefore, in order to fully realize the potential of Tregs in MI treatment, innovative strategies are needed to overcome these limitations.
[0004] The chimeric antigen receptor (CAR) approach combines the advantages of T cell immunotherapy with the specificity of antibodies. By genetically engineering antibody-derived variable regions to signaling and co-stimulatory components of immune receptors, CARs can recognize antigens independently of MHC compatibility, eliminating the need for HLA diversity. In recent years, CARs have not only achieved remarkable success in the treatment of hematological malignancies, but also have shown therapeutic potential as redirected Treg cells in disease states such as Alzheimer's disease, inflammatory bowel disease, vitiligo, multiple sclerosis, and type 1 diabetes. In preclinical studies, CAR-Treg cell therapy has been demonstrated as a promising cell therapy approach for modulating pathological immune responses and restoring immune balance using mouse and humanized mouse models.
[0005] Fibroblast activation protein (FAP) is a cell surface glycoprotein expressed primarily during embryonic development and in situations involving active tissue remodeling, such as wound healing, tissue fibrosis, and various types of tumors. Furthermore, Aghajanian et al. reported that FAP is strongly expressed in fibroblasts in human ventricular tissue from patients with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), whereas FAP expression is minimal in normal human ventricular tissue. Studies have shown that the absence of FAP in fibroblasts reduces cardiac fibrosis, highlighting the important role of FAP in the fibrotic process. This makes FAP an attractive candidate antigen for redirecting therapeutic immune cells to the site of infarcted heart. Summary of the invention
[0006] In view of this, our combination of CAR technology with Tregs targeting FAP-expressing CFs may provide a more specific and safer approach to promote cardiac healing and prevent HF after MI.
[0007] One of the objects of the present invention is to provide a chimeric antigen receptor targeting FAP, wherein the chimeric antigen receptor targeting FAP comprises a single-chain antibody targeting FAP, a CD8α hinge region, a CD8 transmembrane region, a CD28 signal region and a CD3ζ signal region, and its nucleotide sequence is shown in SEQ ID NO.1.
[0008] A second object of the present invention is to provide a recombinant viral vector, which comprises the above-mentioned chimeric antigen receptor targeting FAP.
[0009] The third object of the present invention is to provide a method for preparing the above-mentioned recombinant viral vector, the method comprising the following steps:
[0010] (1) The vector plasmid pLVX-EF1a-mCMV-ZsGreen and the fragment of the nucleotide sequence shown in SEQ ID NO.1 were double-digested and ligated to obtain a recombinant plasmid;
[0011] (2) The recombinant plasmid, packaging plasmid and envelope plasmid obtained in step (1) are co-transfected into eukaryotic cells to obtain a recombinant viral vector.
[0012] Preferably, the double restriction enzyme cutting sites in step (1) are NotI and BamHI.
[0013] More preferably, the eukaryotic cells in step (2) are HEK293T cells.
[0014] A fourth object of the present invention is to provide a host cell, wherein the host cell comprises the above-mentioned recombinant viral vector.
[0015] A fifth object of the present invention is to provide a chimeric antigen receptor regulatory T cell targeting FAP, wherein the regulatory T cell contains the chimeric antigen receptor targeting FAP.
[0016] The sixth object of the present invention is to provide a method for preparing chimeric antigen receptor regulatory T cells targeting FAP, the preparation method comprising the following steps: transducing Treg cells with the recombinant viral vector prepared by the above method.
[0017] The seventh object of the present invention is to provide the use of the above-mentioned chimeric antigen receptor targeting FAP or the above-mentioned recombinant viral vector or the above-mentioned host cell or the above-mentioned chimeric antigen receptor regulatory T cell targeting FAP in the preparation of a product for treating heart disease.
[0018] Preferably, the product is a medicine.
[0019] The inventors used a CAR construct targeting FAP to redirect Tregs to infarcted cardiac tissue. We found that these FAP CAR Tregs effectively accumulated in the damaged heart and controlled the excessive fibrosis and inflammatory response in MI. This is the first breakthrough study that not only highlights the therapeutic potential of CAR Tregs targeting FAP in promoting cardiac healing, but also lays the foundation for CAR Treg therapy of severe MI in the clinical setting.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] CAR Treg technology, through its specific targeting of fibroblast activation protein FAP, directly acts on key cells in the heart repair process, overcoming the limitations of extensive immunosuppression in traditional heart disease treatment methods and improving the precision and safety of treatment. CAR Treg reduces cardiac fibrosis and maintains cardiac structure and function, thereby reducing the degree of cardiac remodeling. At the same time, CAR Treg helps to reduce cardiac inflammation, promote cardiac tissue repair, and improve the quality of cardiac healing by releasing anti-inflammatory and reparative cytokines such as IL10 and TGFβ. In addition, the specific action of CAR Treg reduces the extensive side effects that may be caused by traditional immunosuppressants because they only target specific pathological processes rather than the broad immune system. Injected through the tail vein during the critical period after myocardial infarction, CAR Treg can form significant cell clusters in the damaged heart area, directly participate in cardiac repair, improve the treatment effect, and reduce the potential impact on other organs. The preparation and application process of CARTreg is expected to be implemented in clinical settings, which not only reduces the complexity of treatment but also improves its feasibility in different medical settings. In summary, CAR Treg technology shows significant beneficial effects in the treatment of heart disease, which are achieved through innovative improvements in specific targeting, regulation of inflammation and fibrosis, promotion of cardiac healing, reduction of toxic side effects, and improvement of efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is a map of the vector plasmid pLVX-EF1a-mCMV-ZsGreen in Example 1.
[0023] Figure 2 The transfection efficiency of FAP CAR Treg (FCTR) and MockTreg (MKTR) detected by flow cytometry in Example 1 (green fluorescent protein GFP + cell percentage).
[0024] Figure 3 The left ventricular ejection fraction (EF), left ventricular fractional shortening (FS), left ventricular end-diastolic diameter (LVEDD) and left ventricular end-diastolic volume (LVEDV) of the experimental group and the control group at the second week after MI in Example 2 were measured by ultrasound, and the ratio of heart weight to body weight (HW / BW) and the ratio of heart weight to tibia length (HW / TL) were calculated.
[0025] Figure 4The wheat germ agglutinin (WGA) and cardiac troponin I (cTnI) immunofluorescence staining in Example 2 was used to detect the cross-sectional area of myocardial cells in the border zone of myocardial infarction in each group at the second week after MI, and real-time fluorescence quantitative PCR was used to detect the expression of myocardial hypertrophy-related genes: B-type natriuretic peptide (BNP), A-type natriuretic peptide (ANP), and β-myosin heavy chain (βMHC).
[0026] Figure 5 The Masson staining in Example 2 was used to detect the fibrosis in the myocardial infarction junction area at the second week of MI, and the real-time fluorescence quantitative PCR was used to detect the expression of fibrosis-related genes: α-smooth muscle actin (αSMA) and type I collagen α1 chain (col1a1).
[0027] Figure 6 The real-time fluorescence quantitative PCR in Example 2 was used to detect the expression of inflammation-related genes: interleukin 1β (IL1β), interleukin 6 (IL6), and tumor necrosis factor α (TNFα), and flow cytometry was used to detect the number of effector T cells and macrophages infiltrating the heart.
[0028] Figure 7 The ratio of myofibroblasts in the myocardial infarction border zone (αSMA+Vim+ / Vim+%) and the ratio of total fibroblasts (Vimentin+%) in each group at the first week of MI were detected by immunofluorescence staining of α-smooth muscle actin (αSMA) and vimentin (Vimentin) in Example 2.
[0029] Figure 8 The ratio of different types of collagen was detected by Sirius red staining under polarized light in Example 2.
[0030] Fig. 9 The results of α-smooth muscle actin (αSMA), Ki67 and TUNEL fluorescence staining in Example 2 to detect proliferation or apoptosis of myofibroblasts. DETAILED DESCRIPTION
[0031] Example 1 Application of FAP CAR Treg cells in the treatment of cell damage
[0032] The application includes CAR Treg cells and FAP bound thereto. On the one hand, the cells are targeted to the damaged area through the CAR Treg cells to regulate local inflammation of cardiac damage, and on the other hand, the cells inhibit the transdifferentiation of fibroblasts expressing FAP into myofibroblasts to inhibit excessive fibrosis of the heart.
[0033] The preparation and detection of chimeric antigen receptor regulatory T cells targeting FAP provided in this embodiment include the following steps:
[0034] (1) Molecular structure design
[0035] Construct the FAP-CAR gene sequence (SEQ ID NO.1) targeting FAP, including a single-chain antibody targeting FAP, a CD8α hinge region, a CD8 transmembrane region, a CD28 signaling region, and a CD3ζ signaling region:
[0036] SEQ ID NO.1:
[0037] GCGGCCGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCT
[0038] CCACGCCGCCAGGCCGGACGTGCTGATGACCCAGACCCCTCTGTGGCTGCCTGTGAGC
[0039] CTGGGCGACCAGGCCAGCATCAGCTGCAGGAGCAGCCAGAGCATCGTGCACAGCAACG
[0040] GCAACACCTACCTGGAGTGGTACCTGCAGAAGCCTGGCCAGAGCCCTAAGCTGCTGATC
[0041] TACAAGGTGAGCAACAGGTTCAGCGGCGTGCCTGACAGGTTCAGCGGCAGCGGCAGCG
[0042] GCACCGACTTCACCGTGAAGATCAGCAGGGTGGAGGCCGAGGACCTGGGCGTGTACTA
[0043] CTGCTTCGGCGGCAGCCACGTGCCTTACACCTTCGGCGGCGGCACCAAGCTGGAGATCA
[0044] AGGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCCAGGTGCAGC
[0045] TGAAGGAGAGCGGCGGCCTGGTGCAGCCTGGCGGCAGCCTGAAGCTGAGCTGCGCCG
[0046] CCAGCGGCTTCACCTTCAGCAGCTACGGCATGAGCTGGGTGAGGCAGACCGCCGACAA
[0047] GAGGCTGGAGCTGGTGGCCACCACCAACAACAACGGCGGCGTGACCTACTACCCTGAC
[0048] AGCGTGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACACCCTGTACCTGC
[0049] AGATGAGCAGCCTGCAGAGCGAGGACACCGCCATGTACTACTGCGCCAGGTACGGCTA
[0050] CTACGCCATGGACTACTGGGGCCAGGGCATCAGCGTGACCGTGAGCAGCACCACGACG
[0051] CCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGC
[0052] GCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACT
[0053] TCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGT
[0054] CACTGGTTATCACCCTTTACTGCAATAGTAGAAGGAACAGACTCCTTCAAGTGACTACCA
[0055] TGAACATGACTCCCCGGAGGCCTGGGCTCACTCGAAAGCCTTACCAGCCCTACGCCCCT
[0056] GCCAGAGACTTTGCAGCGTACCGCCCCAGAGTGAAGTTCAGCAGGAGCGCAGACGCCC
[0057] CCGCGTACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGA
[0058] GGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCG
[0059] AGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGG
[0060] AGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATG
[0061] GCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTGAGGATCC.
[0062] (2) Construction of pLVX-EF1a-FAP-CAR-mCMV-ZsGreen plasmid
[0063] ①DNA primer design and synthesis:
[0064] FAP-CAR-NotI-F(SEQ ID NO.2):
[0065] 5'-ATTTGCGGCCGCCACCATGGCCTTACCAGTGACCGCCTTGC-3';
[0066] FAP-CAR-BamHI-R (SEQ ID NO.3):
[0067] 5'-CGCGGATCCTCAGCGAGGGGGCAGGGCCTGCATGTGA-3';
[0068] ② Using the plasmid containing FAP-CAR DNA as a template, PCR amplified the target gene FAP-CAR, introduced NotI and BamHI restriction sites at both ends of the primer, and recovered the target gene FAP-CAR DNA band (SEQ ID NO.1, 1479 bp) by 1% agarose gel.
[0069] ③ Vector plasmid pLVX-EF1a-mCMV-ZsGreen (Plasmid map see Figure 1 , the plasmid was provided by Shanghai Dianjun Biotechnology Co., Ltd.) and double-digested with NotI and BamHI
[0070] The enzyme digestion reaction was carried out in a 37°C water bath for 3 h. The vector enzyme digestion system was as follows:
[0071] Table 1
[0072] Components volume Plasmid pLVX-EF1a-mCMV-ZsGreen 2μg 10×CutSmartBuffer 2μl NotI 1μl B H 1μl <![CDATA[ddH2O]]> Make up to 20 μl
[0073] The large fragment of plasmid pLVX-EF1a-mCMV-ZsGreen digested with NotI+BamHI was recovered by 1% agarose gel electrophoresis.
[0074] ④ Double digestion of the target gene FAP-CAR with NotI and BamHI
[0075] The enzyme digestion reaction was carried out in a 37°C water bath for 3 h. The enzyme digestion system was as follows:
[0076] Table 2
[0077]
[0078]
[0079] The FAP-CARNotI+BamHI digested fragments were recovered by 1% agarose gel electrophoresis.
[0080] ⑤ Connect the large fragment recovered from plasmid pLVX-EF1a-mCMV-ZsGreen to the FAP-CAR fragment. The connection reaction is carried out at 22°C for 3 hours. The connection reaction system is as follows:
[0081] Table 3
[0082] Components volume FAP-CAR fragment 6μl pLVX-EF1a-mCMV-ZsGreen large fragment 2μl 10×LigaseBuffer 1μl <![CDATA[T4 DNA ligase]]> 1μl
[0083] ⑥ Transformation of ligation product: Mix 10ul ligation product with 100ul JM109 competent bacteria, place on ice for 30min, heat shock at 42℃ for 45s, immediately place on ice for 2min, add 400ul LB medium preheated to room temperature, culture at 37℃ constant temperature shaker for 1h, centrifuge at 4000rpm for 1min, discard 400ul culture supernatant, mix the remaining 100ul with a pipette, and evenly spread it on the LB plate containing 100ug / ml Ampicillin resistance, and culture inverted in a 37℃ constant temperature incubator overnight.
[0084] ⑦ Pick 3 single colonies and inoculate them into 5 ml LB culture medium containing 100 μg / ml Ampicillin resistance. Culture them in a constant temperature shaker at 250 rpm and 37°C overnight. Extract the plasmid using a small amount of plasmid extraction kit, and perform restriction enzyme digestion identification with SpeI+BamHI. Pick the positive clones with correct restriction enzyme digestion identification for sequencing verification.
[0085] (2) Lentivirus preparation and packaging
[0086] The pLVX-EF1a-FAP-CAR-mCMV-ZsGreen recombinant plasmid, packaging plasmid psPAX2, and envelope plasmid pMD2G were co-transfected into cultured HEK293T cells. The culture medium was replaced with complete medium without P / S one day before transfection, and then the lentiviral vector plasmid and packaging plasmid were co-transfected into the cells using the CPT high-efficiency transfection kit. After transfection, the cells continued to be cultured, and fresh culture medium was replaced after 24 hours. The supernatant containing the virus was collected after 48 hours, and cell debris and impurities were removed by centrifugation and filtration. Finally, the virus particles were resuspended by ultracentrifugation and appropriate medium, and stored at -80°C after aliquoting for use.
[0087] The biological titer of lentivirus is determined by infecting HEK 293 cells and counting fluorescent cells. Before the experiment, HEK 293 cells were inoculated into 48-well plates, and then the virus was serially diluted using complete medium containing polybrene, and the diluted virus solution was added to the cell wells. After infection overnight, fresh medium was replaced, and culture was continued for 48 hours. The number of fluorescent positive cells was observed and counted using a fluorescence microscope. Based on the number of fluorescent cells and the dilution factor, the titer of the virus can be calculated, that is, the number of transduction units per microliter of virus solution (TU / ml).
[0088] The control group Mock Treg only contained ZsGreen fluorescence but no FAP CAR structure, that is, the plasmid pLVX-EF1a-mCMV-ZsGreen, packaging plasmid psPAX2, and envelope plasmid pMD2G were co-transfected into cultured HEK293T cells.
[0089] (3) Isolation of CD4 + CD25 + Treg cells
[0090] Mouse spleen Treg cells were isolated using Miltenyi magnetic beads, and the purity of Tregs was assessed by flow cytometry, with a purity of over 90%.
[0091] (4) Activation of Treg cells
[0092] Tregs were cultured in 2 ml T cell culture medium at a density of 2 × 10^6 cells per well in a 12-well plate. Tregs were cultured with 1000 U / mL recombinant IL-2 and T cell activator anti-CD3 / CD28 magnetic beads (ratio 2:1).
[0093] (5) Lentiviral transduction of Treg cells to prepare FAP CAR Treg cells
[0094] After 48 hours of culture of Tregs, the cells were transferred to 24-well plates pre-coated with Retronectin (50 μg / ml) and centrifuged at 1000G for 1 hour. Subsequently, the cells were expanded in the presence of 50 U / mL IL-2 for 72-96 hours.
[0095] (6) After preparation, the transduction efficiency of mouse FAP CAR Treg cells (GFP positive rate) was detected by FACS. Figure 2 As shown, the transfection efficiency was 60%-65%. The expression of CD4, CD25, FOXP3 and CTLA-4 in FAP CAR Tregs, MockTregs and Tregs not infected with the virus was compared by flow cytometry, and it was found that lentiviral transduction did not change the suppressive phenotype of Treg itself.
[0096] In addition, to verify the effect of FAP-specific activation of FAP CAR Tregs, a co-culture experiment was performed with a total of 4 groups: (1) Mock Treg co-cultured with 3T3 cell line; (2) Mock Treg co-cultured with 3T3.FAP cells; (3) FAP CAR Treg co-cultured with 3T3 cell line; (4) FAP CAR Treg co-cultured with 3T3.FAP cells; the 3T3.FAP cells were obtained by transferring a recombinant plasmid with a flag tag overexpressing mouse FAP into the 3T3 cell line using lipo3000. After 24 hours, the results showed that FAP CAR Tregs effectively activated 3T3.FAP fibroblasts, showing an increase in the expression of CD69, GARP, and LAP, a response that was not observed in Mock Tregs. These findings highlight the FAP-specific activation of FAP CAR Tregs.
[0097] Example 2
[0098] When constructing a mouse heart injury model in this embodiment, 8-12 week old male c57 mice were used as myocardial infarction (MI) models. The myocardial infarction model was established by permanent ligation of the left anterior descending coronary artery. Briefly, the process involves anesthetizing mice by intraperitoneal injection of ketamine (50 mg / kg) and sodium pentobarbital (50 mg / kg), followed by endotracheal intubation and connection to a rodent ventilator to ensure physiological stability during surgery. The heart was approached by left thoracotomy, and the left anterior descending coronary artery was carefully ligated using fine 6-0 sutures. On the third day after modeling, we injected CAR Treg cells (2.5×10^5 cells per mouse) through the tail vein.
[0099] In this example, an experimental group and a control group were set up. The experimental group used the FAP CAR Treg prepared in Example 1; the control group used Mock Treg cells transduced with an empty lentivirus and a PBS solution for the experiment.
[0100] At 2 weeks after MI modeling, the short-axis and long-axis images of the ventricles of the experimental and control mice were imaged using small animal ultrasound (Vevo3100). We measured the left ventricular ejection fraction (EF), left ventricular fractional shortening (FS), left ventricular end-diastolic diameter (LVEDD), and left ventricular end-diastolic volume (LVEDV) on the short-axis M-mode images captured at the level of the mid-papillary muscles.
[0101] like Figure 3 As shown in the figure, compared with the Mock Treg cells and PBS solution groups, FAP CAR Treg cells significantly improved cardiac function after myocardial infarction. This was manifested by an increase in EF and FS, and a decrease in LVEDV and LVEDD. In addition to the improvement in cardiac function, we also observed that the heart weight to body weight ratio and the heart weight to tibia length ratio were improved in MI mice treated with FAP CAR Tregs compared with mice treated with the control solvent, while mice treated with Mock Tregs did not (see Figure 3 ).
[0102] Immunostaining of cardiac troponin I and wheat germ agglutinin (WGA) showed that on day 14 after MI modeling, the cross-sectional area of cardiomyocytes in the group treated with FAP CAR Tregs was reduced compared with that in the PBS solution group, while there was no significant reduction in the group treated with Mock Tregs, which was accompanied by a simultaneous decrease in the expression of hypertrophic genes such as BNP, ANP, and βMHC (see Figure 4 ).
[0103] Masson trichrome staining of the peri-infarct area showed that cardiac fibrosis was significantly reduced compared with that in the MockTregs-treated mice or the PBS vehicle group, accompanied by decreased αSMA and Col1a1 gene expressions ( Figure 5 ).
[0104] In addition, we observed a decrease in the expression of inflammatory factors (IL1β, IL6, and TNFα) in the injured hearts treated with FAP CAR Tregs, and a reduction in the number of effector T cells in the infarcted myocardium 7 days after MI. At the same time, FAP CAR Tregs injection also reduced the number of infiltrating macrophages ( Figure 6 ). Therefore, our findings consistently demonstrated that CARTregs targeting FAP have a significant anti-inflammatory effect.
[0105] On day 7 after myocardial infarction (MI), immunofluorescence staining showed that the number of myofibroblasts expressing αSMA and Vimentin was significantly reduced in the FAP CAR Treg treatment group. The total number of CFs expressing Vimentin was consistent in the three groups ( Figure 7 In addition, analysis using Sirius Red polarized light microscopy showed that the tightly packed, rigid collagen fibers (orange-red) were reduced in the infarct scars of MI mice treated with FAP CAR Tregs ( Figure 8 ).
[0106] To determine whether the reduction in the number of myofibroblasts in FAP CAR Tregs-treated scar tissue was due to decreased proliferation or increased apoptosis, we performed immunostaining for proliferation (Ki67) and apoptosis (TUNEL) markers. We observed that αSMA expressing Ki67 or TUNEL + Vim + There was no significant difference in the proportion of CFs ( Fig. 9 These findings suggest that the reduced number of myofibroblasts in scar tissue and reduced cardiac fibrosis in FAP CAR Tregs-treated MI mice compared with those in Mock Tregs and control vehicle-treated MI mice may be due to reduced myofibroblast differentiation or formation rather than proliferation or apoptosis.
[0107] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A chimeric antigen receptor targeting FAP, characterized in that The chimeric antigen receptor targeting FAP comprises a single-chain antibody targeting FAP, a CD8α hinge region, a CD8 transmembrane region, a CD28 signal region and a CD3ζ signal region, and its nucleotide sequence is shown in SEQ ID NO.
1.
2. A recombinant viral vector, characterized in that: The recombinant viral vector comprises the FAP-targeting chimeric antigen receptor as described in claim 1.
3. A method for preparing the recombinant viral vector according to claim 2, characterized in that: The method comprises the following steps: (1) The vector plasmid pLVX-EF1a-mCMV-ZsGreen and the fragment of the nucleotide sequence shown in SEQ ID NO.1 were double-digested and ligated to obtain a recombinant plasmid; (2) The recombinant plasmid, packaging plasmid and envelope plasmid obtained in step (1) are co-transfected into eukaryotic cells to obtain a recombinant viral vector.
4. The method according to claim 3, characterized in that The double restriction enzyme cutting sites in step (1) are NotI and BamHI.
5. The method according to claim 4, characterized in that The eukaryotic cells in step (2) are HEK293T cells.
6. A host cell, characterized in that The host cell comprises the recombinant viral vector described in claim 2.
7. A chimeric antigen receptor regulatory T cell targeting FAP, characterized in that: The regulatory T cells contain the FAP-targeting chimeric antigen receptor as claimed in claim 1.
8. A method for preparing chimeric antigen receptor regulatory T cells targeting FAP, characterized in that: The preparation method comprises the following steps: transducing Treg cells with the recombinant viral vector prepared by any one of the methods of claims 3-5.
9. Use of the chimeric antigen receptor targeting FAP according to claim 1, the recombinant viral vector according to claim 2, the host cell according to claim 6, or the chimeric antigen receptor regulatory T cell targeting FAP according to claim 7 in the preparation of a product for treating heart disease.
10. The use according to claim 9, characterized in that: The product described is a drug.
